Tower View Wealth Management LLC Has $2.92 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Tower View Wealth Management LLC boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 132,307 shares of the company’s stock after buying an additional 1,660 shares during the quarter. Tower View Wealth Management LLC owned approximately 0.06% of Cellebrite DI worth $2,915,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Quarry LP acquired a new position in Cellebrite DI during the third quarter worth approximately $27,000. Advisors Asset Management Inc. increased its position in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after buying an additional 1,742 shares during the last quarter. R Squared Ltd acquired a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $100,000. Venturi Wealth Management LLC grew its position in shares of Cellebrite DI by 28.6% in the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock valued at $152,000 after purchasing an additional 2,000 shares during the last quarter. Finally, MQS Management LLC acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $294,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $18.56 on Friday. The business has a fifty day moving average price of $22.31 and a two-hundred day moving average price of $19.61. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30. The stock has a market capitalization of $3.82 billion, a PE ratio of -13.35, a PEG ratio of 4.27 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the topic of several research reports. Craig Hallum upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Friday, February 14th. Finally, Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.